Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use
Authors:
Open Access
- 1 May 2010
- journal article
- practice guideline
- Published by Elsevier in Annals of Oncology
- Vol. 21 (suppl_5) , v244-v247
Abstract
Anaemia is defined as a reduction of the haemoglobin (Hb) concentration, red-cell count or packed cell volume below normal levels.Keywords
This publication has 21 references indexed in Scilit:
- Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysisCanadian Medical Association Journal, 2009
- Erythropoietin in Cancer PatientsAnnual Review of Medicine, 2009
- Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled StudyJournal of Clinical Oncology, 2008
- Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEYEuropean Journal of Haematology, 2006
- Anaemia of Cancer: Impact on Patient Fatigue and Long-Term OutcomeOncology, 2005
- The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patientsEuropean Journal of Cancer, 2004
- Pure Red-Cell Aplasia and Epoetin TherapyNew England Journal of Medicine, 2004
- Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trialBlood, 2004
- Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized TrialJournal of Clinical Oncology, 2004
- Anaemia in cancer: pathophysiology and treatmentCancer Treatment Reviews, 2000